2008
Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow
Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow. Journal Of Nuclear Medicine 2008, 49: 517-523. PMID: 18344436, DOI: 10.2967/jnumed.107.048504.Peer-Reviewed Original ResearchConceptsBlood flowUptake scanPET scansControl ROIMore tumor sitesFirst-pass uptakeTumor blood flowEarly uptakeRegional blood flowNovel antiangiogenic agentsArterial blood concentrationDose-escalating protocolPET molecular imagingMeasured blood flowPerfusion scanEstimate of perfusionBlood concentrationsBolus injectionProstate cancerAntiangiogenic agentsTumor perfusionGlucose metabolismBlood flow analysisBack musclesLarge arteries
2004
ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study
Heymach J, Dong R, Dimery I, Wheeler C, Fidias P, Lu C, Johnson B, Herbst R. ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. Journal Of Clinical Oncology 2004, 22: 3051-3051. DOI: 10.1200/jco.2004.22.14_suppl.3051.Peer-Reviewed Original ResearchZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study
Heymach J, Dong R, Dimery I, Wheeler C, Fidias P, Lu C, Johnson B, Herbst R. ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. Journal Of Clinical Oncology 2004, 22: 3051-3051. DOI: 10.1200/jco.2004.22.90140.3051.Peer-Reviewed Original Research
2003
Surrogate markers in antiangiogenesis clinical trials
Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. British Journal Of Cancer 2003, 89: 8-14. PMID: 12838293, PMCID: PMC2394225, DOI: 10.1038/sj.bjc.6601035.Peer-Reviewed Original Research
2000
9:00—9:15 Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors
Mullani N, Herbst R, Abbruzzese J, Charnsangavej C, Kim E, Tran H, Barron B, Lamki L, Gould K. 9:00—9:15 Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors. Molecular Imaging And Biology 2000, 3: 151. PMID: 11150754, DOI: 10.1016/s1095-0397(00)00063-7.Peer-Reviewed Original ResearchStandard uptake valueTumor blood flowBlood flowGlucose metabolismImaged tumorsTumor-bearing sitesStart of therapyTumor metabolic activityRegional blood flowNovel antiangiogenic agentsDays of treatmentNon-invasive imagingAntiangiogenic treatmentAntiangiogenic agentsPatientsDose levelsUptake valueTumorsHuman tumorsPercentage changePhase IOxygen-15Flourine-18TreatmentDose9:30—9:45 First Pass FDG Measured Blood Flow in Tumors: A Comparison with O-15 Labeled Water Measured Blood Flow
Mullani N, Herbst R, Abbruzzese J, Barron B, Lamki L, Charnsangavej C, Kim E, Tran H, Jiwani A, Gould K. 9:30—9:45 First Pass FDG Measured Blood Flow in Tumors: A Comparison with O-15 Labeled Water Measured Blood Flow. Molecular Imaging And Biology 2000, 3: 153. PMID: 11150756, DOI: 10.1016/s1095-0397(00)00065-0.Peer-Reviewed Original ResearchBlood flowRegional blood flowNovel antiangiogenic agentsBlood flow valuesOne-compartment modelMeasured blood flowAbsence of perfusionBlood flow tracerPerfusion scanEstimate of perfusionBolus injectionAntiangiogenic agentsPET scansTumor perfusionMCi doseLinear regression analysisFDGTumor sitePhase IPerfusion tracerPerfusionTumorsTwo minutesScansRegression analysis